Key result
Only ~8% of HFrEF patients achieve maximal GDMT doses, limited by clinical inertia and side effects.
Why the study?
Real-life patients with HFrEF often fail to reach guideline-recommended target doses of disease-modifying treatments, prompting an investigation into the main reasons for this gap.
Observational (n=266)
No
This registry study highlights that clinical inertia and physiological barriers like low blood pressure and renal dysfunction severely limit the achievement of target GDMT doses in real-world HFrEF patients.
Underscores barriers limiting maximal GDMT in real-world HFrEF; hypothesis-generating for interventions to overcome inertia.
Background Previous studies have shown that real-life patients with HFrEF (Heart Failure with Reduced Ejection Fraction) often fail to reach the target doses of disease-modifying treatments that demonstrate benefits in randomized controlled trials (RCTs), which form the basis of guideline recommendations. The reasons behind this appear to be multifactorial, leading to a gap between guideline recommendations and everyday clinical practice. Purpose This study aimed to investigate the main reasons why patients with HFrEF are not receiving the target doses of guideline-directed medical therapy (GDMT). Methods We conducted a registry-based study including patients with HFrEF hospitalized at our center between September 2021 and September 2023. Information was collected on therapy adherence, doses, and reasons for not achieving target doses. Follow-up data were obtained through clinical visits or phone interviews. Results This study analyzed 266 patients with newly diagnosed HFrEF, and GDMT was initiated according to the ESC (European Society of Cardiology) guidelines. The mean age of the patients was 64 years (IQR 16), and 27.4% were female. Only 7.7% of the patients were on the maximal doses of all four pillars of GDMT. Most patients regularly took their prescribed medication, and adherence did not vary significantly between different groups of medications. The primary reasons for not achieving maximum doses included lack of dosage increase attempts, issues with kidney function and potassium levels and low blood pressure Conclusion The greatest challenges in achieving guideline-directed medical therapy (GDMT) for HFrEF include clinical inertia, side effects, and patients' perceptions of the necessity of medication. Physicians may overestimate the quality of care they provide, contributing to clinical inertia. Other factors include time constraints during office visits, patient nonadherence, and reluctance to adjust therapy. Additionally, gaps in education, training, and organizational support are well-recognized causes of clinical inertia.
No takes yet. Share an insight, caveat, or question.
Galich et al. (2025) conducted an observational in Heart Failure with Reduced Ejection Fraction (HFrEF) (n=266). Guideline-directed medical therapy (GDMT) was evaluated on Achievement of maximal doses of all four pillars of GDMT. Only 7.7% of patients with newly diagnosed HFrEF achieved maximal doses of all four pillars of guideline-directed medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: